Tradestie Institutional Equity Comparison Engine
PLRX vs LYRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PLRX Overall Edge
PLRX Captures Institutional Edge (3โ0 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pliant Therapeutics, Inc. Common Stock (PLRX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, PLRX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, PLRX sits in UNCLASSIFIED (4th %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
PLRX N/M vs LYRA N/M Fwd P/E
Growth & Margin Winner
PLRX
Op Margin 0.0% vs -25032.0% ยท YoY -100.0% vs -87.2%
Momentum & Technical Winner
PLRX
1Y -60.9% vs -94.3% ยท 52W Pos 0% vs 1%
Options & Structure Winner
PLRX
UNCLASSIFIED (4th %ile IV) vs UNCLASSIFIED (N/A IV)
PLRX
NASDAQ
Pliant Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.66
-5.16% 1D
Market Cap
$43.2M
1M Return
-26.84%
1Y Return
-60.87%
Forward P/E
N/M
Unified AI Score
39.0 / 100
SELL
Tech 25.0
Fund 43.0
Flow 63.0
Mom 44.0
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PLRX -60.87%
LYRA -94.34%
Spread: +65.12 pp (PLRX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PLRX Revenue | LYRA Revenue | PLRX Op. Margin | LYRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $60M | N/A | -2.2% | N/A | PLRX |
| FY2020 | $40M | N/A | -99.6% | N/A | PLRX |
| FY2021 | $10M | $0M | -1288.1% | -15303.5% | PLRX |
| FY2022 | $10M | $0M | -1313.4% | -4131.0% | PLRX |
| FY2023 | $0M | $0M | -11654.7% | -4308.1% | LYRA |
| FY2024 | N/A | $0M | N/A | -6280.8% | LYRA |
| FY2025 | N/A | $0M | N/A | -7794.5% | LYRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PLRX | LYRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $43.2M | $2.3M | Larger Scale | PLRX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | -87.2% | Higher Growth | LYRA |
| Operating Margin (TTM) Profitability | 0.0% | -25032.0% | Higher Margin | PLRX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -50.3% | -404.5% | Higher ROE | PLRX |
| 52-Week Range Position Momentum | 0% ($1โ$2) | 1% ($0โ$38) | Stronger Trend | LYRA |
| Beta / 30D Volatility Risk Regime | 0.93ฮฒ ยท 37% Vol | 0.33ฮฒ ยท 248% Vol | Lower Realized Risk | PLRX |
| Unified Institutional Score Composite Signal | 39.0 / 100 (SELL) | 52.2 / 100 (HOLD) | Higher Composite | LYRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PLRX vs LYRA Buy Guide
PLRX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
4th %ile
IV Regime
Compressed (<25th %ile)
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PLRX nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.